Clinical characteristics of patients at baseline and during follow-up stratified for iron supplementation during follow-up.

Mean ±SD [25th, 50th and 75th percentile for cases of non-normal distribution] or number (%).apbpcpdp* Coronary artery disease (CAD): myocardial infarction (MI), percutaneous transluminal coronary angioplasty (PTCA), aortocoronary bypass (ACBP).** Cardiovascular disease (CVD): myocardial infarction (MI), percutaneous transluminal coronary angioplasty (PTCA), aortocoronary bypass (ACBP), coronary artery stenosis ≥50%, ischemic cerebral infarction, transient ischemic attack (TIA)/PRIND.*** Peripheral arterial disease (PAD): vascular stenosis, percutaneous transluminal angioplasty (PTA), peripheral bypass, amputation.‡Follow-up time was calculated as the time from the start of dialysis until the patient died or the end of the observation period was reached.#Cardiovascular mortality: myocardial infarction (MI), heart failure, sudden death, ischemic stroke, hemorrhagic stroke.Clinical characteristics of patients at baseline and during follow-up stratified for iron supplementation during follow-up.